
    
      Patients with active mild to moderate ulcerative colitis that has not responded to a minimum
      of 4 weeks of 5-ASA will be randomized to receive single daily doses of either placebo, 600
      mg SR140333B or 1800 mg of SR140333B for eight weeks. Patients will undergo baseline and end
      of study sigmoidoscopic assessments and complete daily symptom diaries during the study.
      Ulcerative colitis disease activity will be measured by both the overall and component
      subscores of the Mayo Disease Activity Index.
    
  